Skip to main content
Grant Details

Grant Number: 5R01CA142714-04 Interpret this number
Primary Investigator: Ross, Julie
Organization: University Of Minnesota
Project Title: Predictors of Myelodysplastic Syndrome in Minnesota
Fiscal Year: 2013
Back to top


DESCRIPTION (provided by applicant): Myelodysplastic syndrome (MDS) is a heterogeneous disruption of the hematopoietic system that can lead to the development of acute myeloid leukemia (AML) in about 1/3 of cases. MDS became reportable to the Surveillance, Epidemiology and End Results program in 2001. It is estimated that about 10,000 MDS cases are newly diagnosed each year in the United States, which is similar to the number of malignant gliomas. Minnesota has one of the higher incidence rates of MDS. With the exception of chemotherapy and radiation treatment for other cancers, which is associated with < 5% of MDS, little is known about causes. Of the few studies conducted (mostly <200 cases and/or clinic-based), there is a suggestion of a role for occupational exposures, cigarette smoking, and some other lifestyle factors, many of which are similar to those associated with AML. We are proposing a new population-based study of MDS in Minnesota that utilizes the questionnaire and infrastructure of our ongoing adult myeloid leukemia study that concludes in early 2010. A total of 705 MDS cases and 705 frequency-matched population controls will be enrolled over a 4 1/2 year period (April 1, 2010 - October 31, 2014). In addition to evaluating potential risk factors such as those described above, we will explore risk factors by central pathology reviewed subtypes of MDS by integrating data from our adult myeloid leukemia study. We will also determine those environmental or other exogenous risk factors that are common to AML and MDS versus those risk factors that are distinct. Additionally, we will explore whether there are risk factors more common to MDS cases that are at risk of progressing to AML, which includes the novel incorporation of prognostic scoring systems. Finally, we will collect saliva from MDS cases and controls for future genetic susceptibility studies. This study will be the largest population-based study of MDS conducted to date. With the incorporation of a successful infrastructure, and the ability to make comparisons with a similar existing study of myeloid leukemia, we are uniquely positioned to answer important etiological questions regarding MDS. The significance of this proposal also relates to potential prevention strategies for adult AML, which has important public health implications.

Back to top


Chemical Exposures And Risk Of Acute Myeloid Leukemia And Myelodysplastic Syndromes In A Population-based Study
Authors: Poynter J.N. , Richardson M. , Roesler M. , Blair C.K. , Hirsch B. , Nguyen P. , Cioc A. , Cerhan J.R. , Warlick E. .
Source: International Journal Of Cancer, 2017-01-01 00:00:00.0; 140(1), p. 23-33.
PMID: 27603749
Related Citations

Association between mitochondrial DNA haplogroup and myelodysplastic syndromes.
Authors: Poynter J.N. , Richardson M. , Langer E. , Hooten A.J. , Roesler M. , Hirsch B. , Nguyen P.L. , Cioc A. , Warlick E. , Ross J.A. .
Source: Genes, Chromosomes & Cancer, 2016 Sep; 55(9), p. 688-93.
PMID: 27121678
Related Citations

Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes.
Authors: Poynter J.N. , Richardson M. , Blair C.K. , Roesler M.A. , Hirsch B.A. , Nguyen P. , Cioc A. , Warlick E. , Cerhan J.R. , Ross J.A. .
Source: Cancer Epidemiology, 2016 Feb; 40, p. 134-40.
PMID: 26720913
Related Citations

Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota.
Authors: Smith A.R. , Warlick E.D. , Roesler M.A. , Poynter J.N. , Richardson M. , Nguyen P. , Cioc A. , Hirsch B. , Ross J.A. .
Source: Annals Of Hematology, 2015 Oct; 94(10), p. 1667-75.
PMID: 26063191
Related Citations

Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.
Authors: Pease D.F. , Ross J.A. , Poynter J.N. , Nguyen P.L. , Hirsch B. , Cioc A. , Roesler M.A. , Warlick E.D. .
Source: Cancer Epidemiology, 2015 Apr; 39(2), p. 222-8.
PMID: 25701277
Related Citations

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Authors: Gleason M.K. , Ross J.A. , Warlick E.D. , Lund T.C. , Verneris M.R. , Wiernik A. , Spellman S. , Haagenson M.D. , Lenvik A.J. , Litzow M.R. , et al. .
Source: Blood, 2014-05-08 00:00:00.0; 123(19), p. 3016-26.
EPub date: 2014-05-08 00:00:00.0.
PMID: 24652987
Related Citations

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Authors: Wiernik A. , Foley B. , Zhang B. , Verneris M.R. , Warlick E. , Gleason M.K. , Ross J.A. , Luo X. , Weisdorf D.J. , Walcheck B. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2013-07-15 00:00:00.0; 19(14), p. 3844-55.
EPub date: 2013-07-15 00:00:00.0.
PMID: 23690482
Related Citations

Back to Top